Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

fexagratinib (ABSK091)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Abbisko, AstraZeneca

Drug class:

pan-FGFR inhib

Related drugs:

‹

erdafitinib (70)

erdafitinib (70)

›

FGFR1 amplification	Gastric Cancer	FGFR1 amplification	Gastric Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
FGFR2 amplification	Gastroesophageal Cancer	FGFR2 amplification	Gastroesophageal Cancer	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2	ABSK091 Sensitive: C2 – Inclusion Criteria ABSK091 Sensitive : C2
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3	durvalumab + ABSK091 Sensitive: C3 – Early Trials durvalumab + ABSK091 Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR3-TACC3 F17T8	Urothelial Cancer	FGFR3-TACC3 F17T8	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR2 Y376C	Cholangiocarcinoma	FGFR2 Y376C	Cholangiocarcinoma	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR3-TACC3 F17T8	Cervical Cancer	FGFR3-TACC3 F17T8	Cervical Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR3 A393E	Urothelial Cancer	FGFR3 A393E	Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR1 amplification	HER2 Negative Breast Cancer	FGFR1 amplification	HER2 Negative Breast Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3	ABSK091 Sensitive: C3 – Early Trials ABSK091 Sensitive : C3